- Home
- NTNX vs RVPHW Comparison
NTNX vs RVPHW Comparison
Compare NTNX & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTNX
- RVPHW
- Stock Information
- Founded
- NTNX 2009
- RVPHW 2018
- Country
- NTNX United States
- RVPHW United States
- Employees
- NTNX N/A
- RVPHW 14
- Industry
- NTNX Computer Software: Prepackaged Software
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- NTNX Technology
- RVPHW Health Care
- Exchange
- NTNX Nasdaq
- RVPHW Nasdaq
- Market Cap
- NTNX N/A
- RVPHW N/A
- IPO Year
- NTNX 2016
- RVPHW N/A
- Fundamental
- Price
- NTNX $74.29
- RVPHW $0.06
- Analyst Decision
- NTNX Buy
- RVPHW
- Analyst Count
- NTNX 13
- RVPHW 0
- Target Price
- NTNX $85.77
- RVPHW N/A
- AVG Volume (30 Days)
- NTNX 2.1M
- RVPHW 22.4K
- Earning Date
- NTNX 05-28-2025
- RVPHW 03-14-2025
- Dividend Yield
- NTNX N/A
- RVPHW N/A
- EPS Growth
- NTNX N/A
- RVPHW N/A
- EPS
- NTNX N/A
- RVPHW N/A
- Revenue
- NTNX $2,318,206,000.00
- RVPHW N/A
- Revenue This Year
- NTNX $19.14
- RVPHW N/A
- Revenue Next Year
- NTNX $15.55
- RVPHW N/A
- P/E Ratio
- NTNX N/A
- RVPHW N/A
- Revenue Growth
- NTNX 14.81
- RVPHW N/A
- 52 Week Low
- NTNX $43.35
- RVPHW $0.13
- 52 Week High
- NTNX $79.99
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- NTNX 66.34
- RVPHW N/A
- Support Level
- NTNX $71.20
- RVPHW N/A
- Resistance Level
- NTNX $75.27
- RVPHW N/A
- Average True Range (ATR)
- NTNX 1.76
- RVPHW 0.00
- MACD
- NTNX 1.20
- RVPHW 0.00
- Stochastic Oscillator
- NTNX 96.65
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.